I-JBS Science esePennsylvania ithe namuhla ithole umklomelo we-Bridge Award wama-dollar ayizigidi ezi-3 we-Small Business Innovation Research IIB evela ku-National Cancer Institute. Le nkampani yakha umkhiqizo wokuqala we-liquid biopsy, okuwukuhlolwa kwe-DNA yomchamo umdlavuza wamangqamuzana esibindi wakuqala (HCC).
Despite the monitoring plan for high-risk groups (such as patients with chronic hepatitis, cirrhosis, and fatty liver disease), HCC is usually only discovered at an advanced stage. But if HCC can be detected early, the survival rate can be as high as 40%. Although the detection of the biomarker serum alpha-fetoprotein (AFP) currently shows sensitivity, there is still much room for improvement in the early screening of umdlavuza wesibindi. The technology developed by JBS to separate cancer-derived DNA in urine, as well as a special PCR detection method, can more accurately and sensitively detect circulating isisu DNA biomarkers for liver cancer. In a blind pre-validation study, the company stated that if serum AFP is added, the sensitivity of the method will increase to 89%.
I-JBS ithe ibambisene noJames Hamilton weJohns Hopkins University Medical Center kanye noHie-Won Hann waseThomas University Hospital ukuthuthukisa ukuthuthukiswa kokuhlolwa komchamo womdlavuza wesibindi.
https://www.genomeweb.com/molecular-diagnostics/jbs-science-awarded-3m-commercialize-liver-cancer-screening-test#.W62TzNczbIU
